An inhibitor of Cbl-b
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

NX-1607

Item No. 45222

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2,3-dihydro-2-[3-[cis-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[(3S)-3-methyl-1-piperidinyl]methyl]-4-(trifluoromethyl)-1H-isoindol-1-one
CAS Number
2573775-59-2
Synonyms
  • Cbl-b-IN-3
Molecular Formula
C30H34F3N5O
Formula Weight
537.6
Purity
≥95%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Sparingly soluble: 1-10 mg/mlEthanol: Sparingly soluble: 1-10 mg/ml
SMILES
O=C1C2=CC(CN3C[C@H](CCC3)C)=CC(C(F)(F)F)=C2CN1C4=CC=CC([C@@]5(C6=NN=CN6C)C[C@@H](C5)C)=C4
InChi Code
InChI=1S/C30H34F3N5O/c1-19-6-5-9-37(15-19)16-21-10-24-25(26(11-21)30(31,32)33)17-38(27(24)39)23-8-4-7-22(12-23)29(13-20(2)14-29)28-35-34-18-36(28)3/h4,7-8,10-12,18-20H,5-6,9,13-17H2,1-3H3/t19-,20-,29+/m0/s1
InChi Key
HUOLMBXGHHSYHC-QWQFASRJSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $45

    Add

    5 mg

    $180

    Add

    10 mg

    $203

    Add

    25 mg

    $450

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    NX-1607 is an inhibitor of casitas B-lineage lymphoma proto-oncogene b (Cbl-b; IC50 = 3.4 nM), a RING-type E3 ubiquitin ligase that negatively regulates T cell function.1 It increases IL-2 secretion in primary human T cells (EC50 = 180.6 nM). Application of NX-1607 to anti-CD19 chimeric antigen receptor T (CAR-T) cells generated from patients with diffuse large B cell lymphoma (DLBCL) increases the number of CAR-T cells formed during expansion.2 NX-1607 also increases the production of IFN-γ, TNF-α, IL-2, and granzyme B in the same CAR-T cells and enhances the cytotoxicity of the CAR-T cells in Raji, Daudi, and SU-DHL-4 cells. It enhances the antitumoral efficacy of anti-CD19 CAR-T cells in a Raji B cell lymphoma mouse xenograft model. NX-1607 (5 mg/kg) also reduces alanine transaminase (ALT) and aspartate aminotransferase (AST), markers of liver injury, and hepatic fibrosis in methionine- and choline-deficient (MCD) diet, carbon tetrachloride (CCl4), and bile duct ligation (BDL) models of liver fibrosis.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Meng, F., Cao, Z., Liu, J., et al. Discovery and biological evaluation of novel, potent, and orally available CBLB inhibitors. J. Med. Chem. 68(22), 24502-24518 (2025).

    2. Wang, H., Li, F., Feng, Y., et al. Cbl-b inhibition improves manufacturing efficiency and antitumoral efficacy of anti-CD19 CAR-T cells. Int. Immunopharmacol. 147:113971, (2025).

    3. Lu, K., Xu, Y., He, L., et al. Revisiting the role of CBL in liver fibrosis: Unveiling the antifibrotic potential of CBLB inhibitor NX-1607. J. Hepatol. 83(3), e175-e177 (2025).